ZIVO vs. RNAC, TSVT, ALMS, INZY, GLUE, TERN, PVLA, LFCR, TNGX, and GOSS
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Alumis (ALMS), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs.
Cartesian Therapeutics (NASDAQ:RNAC) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
ZIVO Bioscience has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%.
ZIVO Bioscience received 60 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.
In the previous week, Cartesian Therapeutics had 12 more articles in the media than ZIVO Bioscience. MarketBeat recorded 13 mentions for Cartesian Therapeutics and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.05 beat Cartesian Therapeutics' score of 0.38 indicating that ZIVO Bioscience is being referred to more favorably in the news media.
86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ZIVO Bioscience has lower revenue, but higher earnings than Cartesian Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cartesian Therapeutics presently has a consensus target price of $42.50, indicating a potential upside of 352.13%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than ZIVO Bioscience.
Cartesian Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.
Summary
Cartesian Therapeutics beats ZIVO Bioscience on 11 of the 17 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 5/22/2025 by MarketBeat.com Staff
